GlassScriptPhysician profile
Yerusalem Lanier
NPI 1760836290
$5,810.02
in general payments reported to CMS, 2019-2025
25 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 91% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $343 · 2021: $688 · 2022: $647 · 2023: $225 · 2024: $531 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Travel and Lodging: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.52 |
| Travel and Lodging | $1,362.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $3,557.03 | 2019-2025 | Pico, Grafix, Collagenase Santyl |
| Osteomed LLC | $1,084.65 | 2019 | |
| Organogenesis INC. | $397.01 | 2021-2023 | Puraply |
| Medical Device Business Services, INC. | $255.19 | 2024 | |
| Grt US Holding, INC. | $65.64 | 2022 | |
| Depuy Synthes Sales INC. | $58.86 | 2021-2025 | N/A |
| Abbott Laboratories | $32.12 | 2023-2024 | Proclaim |
| Kerecis Limited | $31.71 | 2019-2022 | |
| Paragon 28, INC. | $30.81 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $28.76 | 2021 | |
| Trimed, INC. | $25.89 | 2020 | |
| Averitas Pharma INC. | $25.84 | 2024 | Qutenza |
| Reprise Biomedical, INC. | $22.28 | 2021 | |
| Lifenet Health | $20.88 | 2024 | Theragenesis Wound Matrix |
| Amgen INC. | $20.07 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $19.98 | 2022 | |
| Acumed LLC | $19.60 | 2021 | |
| Abbvie INC. | $19.47 | 2022 | |
| Access Pro Medical, LLC | $16.68 | 2023 | Matriderm |
| Fidia Pharma USA INC. | $14.73 | 2022 | |
| Edwards Lifesciences Corporation | $13.65 | 2023 | |
| Paratek Pharmaceuticals, INC. | $13.24 | 2024 | Nuzyra |
| Integra Lifesciences Corporation | $12.37 | 2021 | |
| Nabriva Therapeutics, Plc | $12.29 | 2021 | |
| Lilly USA, LLC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yerusalem Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.